Condição de saúde bucal e qualidade de vida de pacientes com Leucemia Mieloide Crônica em um Cenro de Referência em Hematologia no Amazonas
Carregando...
Arquivos
Data
Autores
Título da Revista
ISSN da Revista
Título de Volume
Editor
Universidade do Estado do Amazonas
Resumo
Chronic Myeloid Leukemia (CML) is a myeloproliferative disease characterized by the presence of the Philadelphia chromosome (Ph). The management and treatment of patients with CML should be carried out by a multidisciplinary team, including a dental surgeon, whose knowledge of the oral condition profile of these patients becomes important for a better performance in promoting their oral health and consequently also impacting directly or indirectly. indirectly on the quality of life of these patients. Objective: To evaluate the oral health status and quality of life of patients with CML diagnosed at a hematological referral center in Amazonas. Methodology: This is a clinical, cross-sectional descriptive/analytical study that evaluated oral manifestations (OM), DMFT, plaque index (PI), probing depth (PD), Clinical attachment loss (CAL), bleeding on probing (BoP), periodontal diagnosis and oral health-related quality of life (OHIP-14), in patients with CML up to 3 years of imatinib use. Results: A total of 36 patients were evaluated, 52.8% of whom were male, the median age was 57,5 years, 94% had basic education and 72.2% had an income ≤ 239 dollar. The frequency of OM was 5.5% (n=2), being an ulcerated lesion and a pedicular lesion, DMFT index: 9,99, being 17% (n=6) of the total edentulous patients (17%) and 77.7% with dental caries disease (n=28). Of the patients subject to periodontal evaluation (n=30), the following results were observed: PI: 57.5% (±27.37), CAL 3.10 mm (± 0 .35), PD 2.13mm (± 0.28), BoP: 49.4% (±28.92), and predominantly diagnosis of gingivitis 83.3%, being 80% generalized gingivitis and 71.4% with reduced periodontium. The assessment of the impact of weak OHIP-14 on quality of life at 8.9% (n=32). Conclusion: The condition of patients with CML using imatinib up to 3 years was satisfactory considering the high caries and dental caries, although a low frequency of tissue changes that indicate the need for surveillance in this study, which indicates the need for dental surveillance in this population